WORLD HEALTH ENERGY HOLDINGS, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 21, 2011



Attached files
FileFilename
10-Q - 10-Q - WORLD HEALTH ENERGY HOLDINGS, INC.when_10q.htm
EX-32.1 - CERTIFICATION - WORLD HEALTH ENERGY HOLDINGS, INC.when_ex321.htm
EX-32.2 - CERTIFICATION - WORLD HEALTH ENERGY HOLDINGS, INC.when_ex322.htm
EX-31.2 - CERTIFICATION - WORLD HEALTH ENERGY HOLDINGS, INC.when_ex312.htm
EX-31.1 - CERTIFICATION - WORLD HEALTH ENERGY HOLDINGS, INC.when_ex311.htm
EXCEL - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - WORLD HEALTH ENERGY HOLDINGS, INC.R15.htm
v2.3.0.15
Stockholders' Equity (Deficit)
9 Months Ended
Sep. 30, 2011
Notes to Financial Statements 
Stockholders' Equity (Deficit)

 

(4) Stockholders' Equity (Deficit)

 

The Company has the authority to issue 10,000,000 shares of preferred stock, par value $0.0007 per share, which may be divided into series and with the preferences, limitations and relative rights determined by the Board of Directors. At September 30, 2011, 5,000,000 shares of preferred stock shares were issued and outstanding. The Company is authorized to issue 4,500,000,000 shares of common stock, par value $0.0007. At June 30, 2009, 880,000,000 shares were issued and outstanding. In April 2008, the Company increased the authorized common stock from 880,000,000 to 4,500,000,000, par value of $0.0007.

 

In the second quarter 2006, the Company issued 19,000,000 shares of its common stock to a vendor for prepaid services at $0.0016 per share. The aggregate remuneration of $30,400 has been treated as prepaid consulting expenses.

 

In the fourth quarter 2006, the Company issued 25,000,000 shares of its common stock pursuant to a stock purchase agreement at $0.002 per share realizing $50,000 and the Company issued 13,000,000 shares of its common stock to consultants for services at $0.0068 per share. The aggregate remuneration of $88,400 has been treated as stock based compensation and expensed in the current year. Additional paid-in capital includes $272,600 for the transfer of 1,400,000 shares of common stock of Amazon Biotech, Inc., held as an investment by the Company, to three stockholders' of the Company in payment of accrued expenses - stockholders' in the amount of $202,000 and compensation in the amount of $72,000. The stock had a basis of $1,400. Additional paid-in capital includes $6,799,405 for the transfer of 17,000,000 shares of common stock of Mazal, held as an investment by the Company, to two stockholders' in payment of accrued expenses - stockholders' in the amount of $253,550, due to stockholder - asset acquisition in the amount of $1,315,000, loans payable - stockholders' in the amount of $13,709, and compensation in the amount of $5,217,741. The stock had a basis of $595.

 

Included in shares of common stock outstanding at June 30, 2009, are 88,750,000 shares authorized for issuance by the director of the Company which have not been issued by the Company's stock transfer agent, of which 4,842,004 were issued in 2007. In the first quarter 2007, the Company authorized the issuance of 4,000,000 shares of its common stock under an S-8 filing with the Securities and Exchange Commission at $0.0072 per share to the Company's attorney in consideration of accrued legal services, and the Company authorized the issuance of 17,000,000 shares of its common stock under an S-8 filing with the Securities and Exchange Commission at $0.0047 per share for services rendered.

 

In November 2009, the Company issued 250,000,000 shares of its restricted common stock to an  employee for $89,300 in accrued salary, $160,700 in accrued salary with two affiliates at $0.001 per share. The Company has recorded the $160,700 as an asset due from the affiliates. In November 2009, the Company issued 220,000,000 shares of its restricted common stock to an officer of the Company for $765,250 in accrued salary, $81,263 in loan payable to said officer and $17,881 in accrued expenses reimbursable to said officer at $0.0039 per share. In November 2009, the Company issued 125,000,000 shares of its restricted common stock to an outsider in settlement of $425,000 of a lawsuit judgement and $115,438 in accrued expenses payable for $0.0043 per share. In November 2009, the Company issued 105,000,000 shares of its restricted common stock to an  employee for $146,000  in accrued salary and $158,670 in loans payable for $0.0029 per share. In November 2009, the Company issued 50,000,000 shares of its restricted common stock to an outsider to complete the acquisition of WHE, valued at $300,000 or $0.006 per share. These shares were approved to be issued in the first quarter of 2007, at the time of the acquisition. In November 2009, the Company issued 40,000,000 shares of its restricted common stock to an outsider for $83,510 in loans payable or $0.0021 per share. In November 2009, the Company issued 30,000,000 shares of its restricted common stock to an outsider for $30,000 in accrued expenses or $0.001 per share. In November 2009, the Company issued 30,000,000 shares of its restricted common stock to a second outsider for $30,000 in accrued expenses or $0.001 per share. In November 2009, the Company issued 25,000,000 shares of its restricted common stock to an outsider for $25,000 in accrued expenses or $0.001 per share. In November 2009, the Company issued 20,000,000 shares of its restricted common stock to an outsider for $20,000 in accrued expenses or $0.001 per share. In November 2009, the Company issued 20,000,000 shares of its restricted common stock to an outsider for $10,000 in accrued expenses or $0.0005 per share. In November 2009, the Company issued 15,000,000 shares of its restricted common stock to an outsider for $15,000 in accrued expenses or $0.001 per share.

 

In 2010, the Company entered into an agreement to acquire 100% of the issued and outstanding common stock of GNE-India from GNE-Cyprus. This agreement calls for the Company to issue 18,000,000,000 shares of the Company’s common stock. In the fall of 2010 the Company issued 2,447,994,016 of these shares with the remaining 15,552,005,984 shares to be issued once the Company increases its authorized from 4,500,000,000 to some amount above 21,000,000,000. The Company valued this transaction by the shares to be issued priced at the average price per share of the shares issued in November 2009, $0.002659, as no other transactions in the Company’s common stock occurred between these dates. This valued the transaction at $47,862,000. The Company has recorded goodwill in the amount of $47,830,000 as a result of this transaction.

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by WORLD HEALTH ENERGY HOLDINGS, INC. and has no official or unofficial affiliation with WORLD HEALTH ENERGY HOLDINGS, INC.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.